Cyclacel Pharmaceuticals, Inc.
CYCC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -89.8% | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | -$0 | -$0 |
| % Margin | 100% | 100% | – | – |
| R&D Expenses | $7 | $19 | $20 | $15 |
| G&A Expenses | $5 | $7 | $7 | $7 |
| SG&A Expenses | $5 | $7 | $7 | $7 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $12 | $26 | $28 | $22 |
| Operating Income | -$12 | -$25 | -$28 | -$23 |
| % Margin | -27,916.3% | -6,060.2% | – | – |
| Other Income/Exp. Net | $0 | -$0 | $2 | $0 |
| Pre-Tax Income | -$12 | -$26 | -$26 | -$22 |
| Tax Expense | -$1 | -$3 | -$5 | -$4 |
| Net Income | -$11 | -$23 | -$21 | -$19 |
| % Margin | -26,074.4% | -5,370.2% | – | – |
| EPS | -1.36 | -28.67 | -28.5 | -32.1 |
| % Growth | 95.3% | -0.6% | 11.2% | – |
| EPS Diluted | -1.36 | -28.67 | -28.5 | -32.1 |
| Weighted Avg Shares Out | 8 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 8 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$12 | -$25 | -$28 | -$23 |
| % Margin | -27,902.3% | -6,052.9% | – | – |